Cronos Group Launches New Spinach PUFFERZ Vape
Cronos Group announced the launch of its newest all-in-one vape, Spinach PUFFERZ. The company said, "The latest innovation under Cronos' Spinach brand brings together high-quality cannabis infused with liquid diamonds in a convenient all-in-one device. Crafted for modern cannabis consumers who value functionality and design, Spinach PUFFERZ offers a seamless way to enjoy high-quality cannabis vape extracts and bold flavors. Every design element was carefully considered to deliver a differentiated experience. Spinach PUFFERZ is Cronos' first AIO vape featuring the increasingly popular palm-style hardware. The device boasts a uniquely satisfying squishy grip with a puffy exterior, a dual ceramic coil for maximum flavor and smooth draws, a boost button for temperature control, and a battery meter to indicate when a charge is needed." Available now in Alberta, British Columbia, and Ontario, Spinach PUFFERZ will be available nationally by April 2026.
Trade with 70% Backtested Accuracy
Analyst Views on CRON
About CRON
About the author

- Product Innovation: Cronos has launched the Spinach PUFFERZ™ all-in-one vape, which combines high-quality cannabis infused with liquid diamonds, delivering a THC concentration of 98.1%, aimed at meeting modern consumers' dual demands for functionality and design, thereby reinforcing its leadership in the Canadian cannabis market.
- Flavor Diversity: The product will be available in three flavors: Sour Blue Razz, Tropical AF, and Pineapple Coconut, each inspired by different strains, designed to attract a broad consumer base and enhance brand loyalty and market share.
- Market Rollout Plan: Spinach PUFFERZ™ is currently available in Alberta, British Columbia, and Ontario, with a national launch expected by April 2026, demonstrating Cronos's strong commitment to market expansion.
- Brand Strategy: Cronos aims to enhance its brand image through continuous innovation and quality products; the launch of Spinach PUFFERZ™ not only showcases its technological prowess in the vape sector but also indicates the company's strategic positioning in the rapidly growing all-in-one vape market.
- Market Size Projection: The global functional food and beverage market is projected to reach approximately $438 billion by 2026, expanding at an annual rate of 10.65%, indicating a significant consumer shift away from conventional delivery formats.
- New Product Launch: Doseology Sciences recently initiated pilot production of caffeine-based energy pouches in January 2026, marking the Feed That Brain brand's entry into the rapidly growing oral pouch category, which is expected to attract demand for portable alternatives.
- Strategic Acquisition: Doseology Sciences acquired the Feed That Brain brand for $400,000 in August 2025, fully paid through stock issuance, aiming to leverage its strengths in functional product design to drive new product commercialization.
- Market Trend Support: The global energy drinks market is expected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, reflecting rising consumer demand for alternative caffeine delivery methods, which further supports Doseology's market strategy.
- Earnings Call Announcement: Cronos Group will hold its Q4 2025 earnings conference call on February 26, 2026, at 8:30 a.m. ET, where senior management will discuss financial results and answer investor questions, reflecting the company's commitment to transparency and investor relations.
- Participation Details: Participants are encouraged to dial in 15 minutes early to avoid delays, and the webcast will be archived on the company's website for later access, ensuring all investors can obtain key information.
- Brand Portfolio Overview: Cronos is focused on building disruptive intellectual property through cannabis research, technology, and product development, with brands like Spinach®, PEACE NATURALS®, and Lord Jones®, showcasing its innovative capabilities in the global cannabis industry.
- Forward-Looking Statements: The press release includes forward-looking statements indicating Cronos' intention to build an iconic international brand portfolio and develop disruptive intellectual property, although these statements are based on reasonable estimates and assumptions, they are subject to significant business and economic risks, requiring investor caution.
- Aurora Financial Performance: Aurora Cannabis reported net revenue of $94.2 million for Q3 2026, a 7% year-over-year increase, with global medical cannabis sales reaching $76.2 million, accounting for over 80% of total sales, indicating strong growth potential in the high-margin medical market.
- Strategic Transformation Plan: Aurora announced plans to gradually exit select Canadian consumer cannabis markets to reduce sales and marketing costs, which is expected to significantly improve overall profit margins in the coming quarters.
- Canopy Growth Results: Canopy Growth reported net revenue of $90.4 million for Q3 2026, with a nearly 50% reduction in net loss despite weak international performance, reflecting positive progress in cost control and market integration.
- Cronos Brand Expansion: Cronos Group launched its premium Lord Jones brand in Israel, marking a significant step in its global expansion strategy aimed at meeting local market demands with high-quality products while enhancing brand recognition in international markets.
- Brand Expansion: Cronos Group has launched its premium cannabis brand Lord Jones® in Israel, marking a strategic expansion into one of the world's most advanced medical cannabis markets, aimed at meeting local demand and enhancing its global brand presence.
- Quality Commitment: The Lord Jones® cannabis flower is produced through carefully selected genetics and small-batch indoor cultivation, ensuring each batch undergoes rigorous testing and hand packaging to maintain aroma and quality, thereby enhancing trust among patients and pharmacists.
- Market Strategy: The launch introduces five premium indoor-grown flower strains and plans for future limited-edition products, demonstrating Cronos' long-term commitment to the Israeli market and its keen insight into the demand for high-end products.
- International Vision: CEO Mike Gorenstein emphasized Israel's key role in the company's borderless product strategy, with this expansion reflecting Cronos' determination and execution in promoting high-quality cannabis brands globally.
- Revenue Overview: Altria generated approximately $6.1 billion in revenue in Q3 2025, with its tobacco business contributing about $5.4 billion, highlighting the company's heavy reliance on this segment, while the ongoing decline in tobacco volumes poses a significant threat to future growth.
- Volume Decline: The company's cigarette volumes fell by 8.2% year-over-year in Q3 2025, with a 10.6% drop over the first nine months, indicating severe challenges in its core business that force it to raise prices to offset the impact of declining sales.
- Strategic Missteps: Altria's decision to spin off its international operations to Philip Morris International resulted in losing its most lucrative market while simultaneously creating a new competitor, reflecting significant errors in strategic decision-making.
- Investment Risks: Altria's investments in the vaping and marijuana sectors have both resulted in losses, particularly with Juul and Cronos Group, leading to substantial charges for shareholders, which exacerbates the company's difficulties in finding long-term growth avenues.









